Akorn Reaches New 52-Week High (AKRX)

NEW YORK ( TheStreet) -- Akorn (Nasdaq: AKRX) hit a new 52-week high Wednesday as it is currently trading at $12.97, above its previous 52-week high of $12.91 with 45,760 shares traded as of 9:45 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.

Akorn has a market cap of $1.07 billion and is part of the health care sector and drugs industry. Shares are up 13.4% year to date as of the close of trading on Tuesday.

Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic pharmaceutical products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. The company has a P/E ratio of 21, above the average drugs industry P/E ratio of 18.7 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Akorn as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Akorn Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Teva, Mylan Seen to Stay on M&A Sidelines

Merger Buzz Drives Akorn to Top of Health Chart in April

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

European Stocks High on French Perfume and Trump Bump

Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More